Pharmacokinetics, Tolerability and Safety of NEX-18a
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety, tolerability and pharmacokinetics of NEX-18a, a
long-acting injectable azacitidine, in patients diagnosed with intermediate 2 or higher-risk
MDS, CMML, or AML and already on treatment with azacitidine.